AbbVie Inc. Increase (Decrease) in Accounts Payable and Accrued Liabilities
AbbVie Inc. (ABBV) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$392.00 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-03.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-03
- AbbVie Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $1.20B, a 133.40% increase year-over-year.
- AbbVie Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$1.59B.
- AbbVie Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$598.00M, a 147.96% decline year-over-year.
- AbbVie Inc. increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $1.73B, a 547.94% increase year-over-year.
- AbbVie Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $951.00M, a 437.29% increase from fiscal 2024.
- AbbVie Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was $177.00M, a 95.39% decline from fiscal 2023.
- AbbVie Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $3.84B, a 117.07% increase from fiscal 2022.
- AbbVie Inc. increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was $1.77B, a 2.91% increase from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $1.20B derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$392.00M 10-Q · filed 2026-08-03 | -$990.00M derived: sum of 3 quarters · filed 2026-08-03 | $740.00M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2026-03-31 | -$1.59B 10-Q · filed 2026-05-08 | -$2.19B derived: sum of 2 quarters · filed 2026-05-08 | -$462.00M derived: sum of 3 quarters · filed 2026-05-08 | $53.00M derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-12-31 | -$598.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.13B derived: sum of 2 quarters · filed 2026-02-20 | $1.65B derived: sum of 3 quarters · filed 2026-08-03 | $951.00M 10-K · filed 2026-02-20 | ||||
| 2025-09-30 | $1.73B derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | $2.25B derived: sum of 2 quarters · filed 2026-08-03 | $1.55B 10-Q · filed 2025-11-04 | $2.80B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-06-30 | $515.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-03 | -$181.00M 10-Q · filed 2026-08-03 | $1.07B derived: sum of 3 quarters · filed 2026-08-03 | $1.33B derived: sum of 4 quarters · filed 2026-08-03 | ||||
| 2025-03-31 | -$696.00M 10-Q · filed 2026-05-08 | $551.00M derived: sum of 2 quarters · filed 2026-05-08 | $818.00M derived: sum of 3 quarters · filed 2026-05-08 | -$881.00M derived: sum of 4 quarters · filed 2026-05-08 | ||||
| 2024-12-31 | $1.25B derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $1.51B derived: sum of 2 quarters · filed 2026-02-20 | -$185.00M derived: sum of 3 quarters · filed 2026-02-20 | $177.00M 10-K · filed 2026-02-20 | ||||
| 2024-09-30 | $267.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-04 | -$1.43B derived: sum of 2 quarters · filed 2025-11-04 | -$1.07B 10-Q · filed 2025-11-04 | -$891.00M derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-06-30 | -$1.70B derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-04 | -$1.34B 10-Q · filed 2025-08-04 | -$1.16B derived: sum of 3 quarters · filed 2026-02-20 | $1.38B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2024-03-31 | $362.00M 10-Q · filed 2025-05-09 | $541.00M derived: sum of 2 quarters · filed 2026-02-20 | $3.08B derived: sum of 3 quarters · filed 2026-02-20 | $4.65B derived: sum of 4 quarters · filed 2026-02-20 | ||||
| 2023-12-31 | $179.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-20 | $2.72B derived: sum of 2 quarters · filed 2026-02-20 | $4.29B derived: sum of 3 quarters · filed 2026-02-20 | $3.84B 10-K · filed 2026-02-20 | ||||
| 2023-09-30 | $2.54B derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-04 | $4.11B derived: sum of 2 quarters · filed 2024-11-04 | $3.66B 10-Q · filed 2024-11-04 | $4.94B derived: sum of 4 quarters · filed 2025-02-14 | ||||
| 2023-06-30 | $1.57B derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-07 | $1.12B 10-Q · filed 2024-08-07 | $1.11B 10-Q · filed 2023-08-07 | $2.40B derived: sum of 3 quarters · filed 2025-02-14 | $3.34B derived: sum of 4 quarters · filed 2025-02-14 | |||
| 2023-03-31 | -$451.00M 10-Q · filed 2024-05-03 | -$465.00M 10-Q · filed 2023-05-05 | $827.00M derived: sum of 2 quarters · filed 2025-02-14 | $1.77B derived: sum of 3 quarters · filed 2025-02-14 | $1.58B derived: sum of 4 quarters · filed 2025-02-14 | |||
| 2022-12-31 | $1.28B derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-14 | $2.22B derived: sum of 2 quarters · filed 2025-02-14 | $2.03B derived: sum of 3 quarters · filed 2025-02-14 | $1.77B 10-K · filed 2025-02-14 | $1.60B 10-K · filed 2023-02-17 | |||
| 2022-09-30 | $939.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-06 | $749.00M derived: sum of 2 quarters · filed 2023-11-06 | $491.00M 10-Q · filed 2023-11-06 | $330.00M 10-Q · filed 2022-11-04 | $756.00M derived: sum of 4 quarters · filed 2024-02-20 | |||
| 2022-06-30 | -$190.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-07 | -$448.00M 10-Q · filed 2023-08-07 | -$183.00M derived: sum of 3 quarters · filed 2024-02-20 | $963.00M derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2022-03-31 | -$258.00M 10-Q · filed 2023-05-05 | $7.00M derived: sum of 2 quarters · filed 2024-02-20 | $1.15B derived: sum of 3 quarters · filed 2024-02-20 | $1.23B derived: sum of 4 quarters · filed 2024-02-20 | ||||
| 2021-12-31 | $265.00M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-20 | $1.41B derived: sum of 2 quarters · filed 2024-02-20 | $1.48B derived: sum of 3 quarters · filed 2024-02-20 | $1.72B 10-K · filed 2024-02-20 | $1.63B 10-K · filed 2022-02-18 | |||
| 2021-09-30 | $1.15B derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $1.22B derived: sum of 2 quarters · filed 2022-11-04 | $1.45B 10-Q · filed 2022-11-04 | $1.06B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-06-30 | $72.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $308.00M 10-Q · filed 2022-08-04 | -$81.00M derived: sum of 3 quarters · filed 2023-02-17 | $1.36B derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2021-03-31 | $236.00M 10-Q · filed 2022-05-06 | -$153.00M derived: sum of 2 quarters · filed 2023-02-17 | $1.28B derived: sum of 3 quarters · filed 2023-02-17 | $725.00M derived: sum of 4 quarters · filed 2023-02-17 | ||||
| 2020-12-31 | -$389.00M derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-17 | $1.05B derived: sum of 2 quarters · filed 2023-02-17 | $489.00M derived: sum of 3 quarters · filed 2023-02-17 | $1.51B 10-K · filed 2023-02-17 | ||||
| 2020-09-30 | $1.44B derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-02 | $878.00M derived: sum of 2 quarters · filed 2021-11-02 | $1.90B 10-Q · filed 2021-11-02 | $1.51B derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-06-30 | -$559.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-02 | $466.00M 10-Q · filed 2021-08-02 | $69.00M derived: sum of 3 quarters · filed 2022-02-18 | $929.00M derived: sum of 4 quarters · filed 2022-02-18 | ||||
| 2020-03-31 | $1.02B 10-Q · filed 2021-05-07 | $1.06B 10-Q · filed 2020-05-08 | $628.00M derived: sum of 2 quarters · filed 2022-02-18 | $1.49B derived: sum of 3 quarters · filed 2022-02-18 | $1.03B derived: sum of 4 quarters · filed 2022-02-18 | |||
| 2019-12-31 | -$397.00M derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-18 | $463.00M derived: sum of 2 quarters · filed 2022-02-18 | $3.00M derived: sum of 3 quarters · filed 2022-02-18 | $97.00M 10-K · filed 2022-02-18 | -$1.12B 10-K · filed 2020-02-21 | |||
| 2019-09-30 | $860.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $400.00M derived: sum of 2 quarters · filed 2020-11-04 | $494.00M 10-Q · filed 2020-11-04 | -$582.00M 10-Q · filed 2019-11-06 | $347.00M derived: sum of 4 quarters · filed 2021-02-19 | |||
| 2019-06-30 | -$460.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-04 | -$366.00M 10-Q · filed 2020-08-04 | -$1.29B 10-Q · filed 2019-08-05 | -$513.00M derived: sum of 3 quarters · filed 2021-02-19 | $356.00M derived: sum of 4 quarters · filed 2021-02-19 | |||
| 2019-03-31 | $94.00M 10-Q · filed 2020-05-08 | -$53.00M derived: sum of 2 quarters · filed 2021-02-19 | $816.00M derived: sum of 3 quarters · filed 2021-02-19 | $637.00M derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2018-12-31 | -$147.00M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-19 | $722.00M derived: sum of 2 quarters · filed 2021-02-19 | $543.00M derived: sum of 3 quarters · filed 2021-02-19 | $734.00M 10-K · filed 2021-02-19 | $190.00M 10-K · filed 2019-02-27 | |||
| 2018-09-30 | $869.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | $690.00M derived: sum of 2 quarters · filed 2019-11-06 | $881.00M 10-Q · filed 2019-11-06 | $862.00M derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2018-06-30 | -$179.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-05 | $12.00M 10-Q · filed 2019-08-05 | -$7.00M derived: sum of 3 quarters · filed 2020-02-21 | $967.00M derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2018-03-31 | $191.00M 10-Q · filed 2019-05-03 | $172.00M derived: sum of 2 quarters · filed 2020-02-21 | $1.15B derived: sum of 3 quarters · filed 2020-02-21 | $882.00M derived: sum of 4 quarters · filed 2020-02-21 | ||||
| 2017-12-31 | -$19.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-21 | $955.00M derived: sum of 2 quarters · filed 2020-02-21 | $691.00M derived: sum of 3 quarters · filed 2020-02-21 | $425.00M 10-K · filed 2020-02-21 | ||||
| 2017-09-30 | $974.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-07 | $710.00M derived: sum of 2 quarters · filed 2018-11-07 | $444.00M 10-Q · filed 2018-11-07 | $232.00M derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-06-30 | -$264.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-07 | -$530.00M 10-Q · filed 2018-08-07 | -$742.00M derived: sum of 3 quarters · filed 2019-02-27 | -$1.81B derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2017-03-31 | -$266.00M 10-Q · filed 2018-05-04 | -$478.00M derived: sum of 2 quarters · filed 2019-02-27 | -$1.54B derived: sum of 3 quarters · filed 2019-02-27 | -$1.50B derived: sum of 4 quarters · filed 2019-02-27 | ||||
| 2016-12-31 | -$212.00M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-27 | -$1.28B derived: sum of 2 quarters · filed 2019-02-27 | -$1.23B derived: sum of 3 quarters · filed 2019-02-27 | -$1.19B 10-K · filed 2019-02-27 | ||||
| 2016-09-30 | -$1.06B derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-07 | -$1.02B derived: sum of 2 quarters · filed 2017-11-07 | -$975.00M 10-Q · filed 2017-11-07 | -$800.00M derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-06-30 | $47.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-07 | $89.00M 10-Q · filed 2017-08-07 | $264.00M derived: sum of 3 quarters · filed 2018-02-16 | $1.18B derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2016-03-31 | $42.00M 10-Q · filed 2017-05-05 | $217.00M derived: sum of 2 quarters · filed 2018-02-16 | $1.14B derived: sum of 3 quarters · filed 2018-02-16 | $1.36B derived: sum of 4 quarters · filed 2018-02-16 | ||||
| 2015-12-31 | $175.00M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-16 | $1.09B derived: sum of 2 quarters · filed 2018-02-16 | $1.31B derived: sum of 3 quarters · filed 2018-02-16 | $1.50B 10-K · filed 2018-02-16 | ||||
| 2015-09-30 | $919.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-07 | $1.14B derived: sum of 2 quarters · filed 2016-11-07 | $1.33B 10-Q · filed 2016-11-07 | $1.14B derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-06-30 | $221.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-05 | $409.00M 10-Q · filed 2016-08-05 | $217.00M derived: sum of 3 quarters · filed 2017-02-17 | $433.00M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2015-03-31 | $188.00M 10-Q · filed 2016-05-06 | -$4.00M derived: sum of 2 quarters · filed 2017-02-17 | $212.00M derived: sum of 3 quarters · filed 2017-02-17 | $607.00M derived: sum of 4 quarters · filed 2017-02-17 | ||||
| 2014-12-31 | -$192.00M derived: 10-K 12 month − 10-Q 9 month · filed 2017-02-17 | $24.00M derived: sum of 2 quarters · filed 2017-02-17 | $419.00M derived: sum of 3 quarters · filed 2017-02-17 | -$193.00M 10-K · filed 2017-02-17 | ||||
| 2014-09-30 | $216.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2015-11-06 | $611.00M derived: sum of 2 quarters · filed 2015-11-06 | -$1.00M 10-Q · filed 2015-11-06 | -$654.00M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-06-30 | $395.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2015-08-07 | -$217.00M 10-Q · filed 2015-08-07 | -$870.00M derived: sum of 3 quarters · filed 2016-02-19 | -$461.00M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2014-03-31 | -$612.00M 10-Q · filed 2015-05-08 | -$1.26B derived: sum of 2 quarters · filed 2016-02-19 | -$856.00M derived: sum of 3 quarters · filed 2016-02-19 | -$832.00M derived: sum of 4 quarters · filed 2016-02-19 | ||||
| 2013-12-31 | -$653.00M derived: 10-K 12 month − 10-Q 9 month · filed 2016-02-19 | -$244.00M derived: sum of 2 quarters · filed 2016-02-19 | -$220.00M derived: sum of 3 quarters · filed 2016-02-19 | -$426.00M 10-K · filed 2016-02-19 | ||||
| 2013-09-30 | $409.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2014-11-07 | $433.00M derived: sum of 2 quarters · filed 2014-11-07 | $227.00M 10-Q · filed 2014-11-07 | -$270.00M derived: sum of 4 quarters · filed 2015-02-20 | ||||
| 2013-06-30 | $24.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2014-08-07 | -$182.00M 10-Q · filed 2014-08-07 | -$679.00M derived: sum of 3 quarters · filed 2015-02-20 | -$239.00M derived: sum of 4 quarters · filed 2015-02-20 | ||||
| 2013-03-31 | -$206.00M 10-Q · filed 2014-05-09 | -$703.00M derived: sum of 2 quarters · filed 2015-02-20 | -$263.00M derived: sum of 3 quarters · filed 2015-02-20 | -$925.00M derived: sum of 4 quarters · filed 2015-02-20 | ||||
| 2012-12-31 | -$497.00M derived: 10-K 12 month − 10-Q 9 month · filed 2015-02-20 | -$57.00M derived: sum of 2 quarters · filed 2015-02-20 | -$719.00M derived: sum of 3 quarters · filed 2015-02-20 | -$731.00M 10-K · filed 2015-02-20 | ||||
| 2012-09-30 | $440.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2013-11-12 | -$222.00M derived: sum of 2 quarters · filed 2013-11-12 | -$234.00M 10-Q · filed 2013-11-12 | |||||
| 2012-06-30 | -$662.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2013-08-09 | -$674.00M 10-Q · filed 2013-08-09 | ||||||
| 2012-03-31 | -$12.00M 10-Q · filed 2013-05-08 | |||||||
| 2011-12-31 | $1.50B 10-K · filed 2014-02-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Merck & Co., Inc. (MRK) | United States | $365.215B | 99.96 |
| JOHNSON & JOHNSON (JNJ) | United States | $652.528B | 29.10 |
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |